Federal Circuit Weighs Implications of Reissued Patent Expirations in Pharmaceutical Sector

The Federal Circuit is currently deliberating on a significant legal question regarding the expiration of reissued patents. This issue arose after arguments were presented by the pharmaceutical giant Merck and generic-drug manufacturers seeking to challenge Merck’s monopoly over a highly lucrative drug used to counteract anesthesia effects. The decision will have implications for patent law and pharmaceutical industry practices, particularly on how long reissued patents can extend the exclusivity on critical drugs. More details about the arguments and the potential impact can be found in the full article on Law360.